Picture EBD Group BIO-Europe 2021 Digital BEU2021 650x80
Document › Details

ERS Genomics Ltd.. (9/14/20). "Press Release: ERS Genomics Provides Comment on US Patent Office Motions Decisions in CRISPR/Cas9 Interference Case". Dublin.

Region Region United States (USA)
Organisations Organisation ERS Genomics Ltd.
  Organisation 2 Broad Institute (MIT / Harvard)
  Group MIT (Massachusetts Institute of Technology)
Products Product CRISPR gene editing technology
  Product 2 IP services
Persons Person Charpentier, Emmanuelle (Helmholtz 201412 Professor at HZI)
  Person 2 Rhodes, Eric (ERS Genomics 201606– CEO before Horizon Discovery since 201201 before Sigma-Aldrich + Sangamo Biosciences)

ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property held by Dr. Emmanuelle Charpentier, has today provided comment on the US Patent and Trademark Office (USPTO/PTAB) rulings in the motions phase of the ongoing patent interference between the University of California, the University of Vienna, and Dr. Emmanuelle Charpentier (collectively, CVC), and the Broad Institute, Harvard University, and the Massachusetts Institute of Technology (collectively, Broad).

In its ruling, the PTAB rejected the majority of Broad's motions, including most importantly a motion that sought to prevent the interference from proceeding. CVC still remains junior party in the interference, which means procedurally that CVC will be required to file its proofs of inventorship first. The designation of Junior and Senior party is a procedural issue at this stage and is not a finding of prior inventorship. The PTAB decision does not affect CVC’s 33 issued US patents, none of which are involved in the interference.

“We are pleased that the PTAB has decided to allow the interference to continue," commented Eric Rhodes, Chief Executive Officer, ERS Genomics. He added: “We remain convinced that the descriptions provided in the Charpentier and Doudna publications were the key guidance that led over ten groups to simultaneously and independently achieve rapid success in eukaryotes. This view appears to be shared outside the US with CVC maintaining a dominant patent position in Europe, Japan, China, and elsewhere. With our 33 issued US patents, none of which are involved in this interference, the CVC family of patents remains the world's most fundamental collection of intellectual property to this exciting technology.”

Record changed: 2020-09-28


Picture EBD Group Global Partnering Four Events One Price 650x80

More documents for ERS Genomics Ltd.

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Demy-Colton BioFuture 2021 NYC A October 650x80px

» top